Search
Monte Rosa Therapeutics Inc
GLUEAdd to Watchlist
12.130USD
-0.470-3.73%
Close 09-18 16:00（ET）
1.03BMarket Cap
LossP/E TTM
After-hours 16:04 (ET)12.250USD+0.125+1.03%
After-hours 16:04 (ET)Monte Rosa Therapeutics Inc (GLUE) Stock Price Target & Forecast
Analyst Rating
Based on 9 analysts giving stock ratings to Monte Rosa Therapeutics Inc in the past month.
Buy
3 Strong Buy
6 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
28.800USD+121.71%
GLUE Analyst Recommendation Trends
In the current month, GLUE has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GLUE average Analyst price target in the last month is 28.800.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
3
3
3
3
3
3
3
3
6
6
6
6
6
6
6
5
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9
9
9
9
9
9
9
9
GLUE Analyst Rating for Peer Comparison
Updated: Sep 18, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Ascendis Pharma A/S
ASND
10
10
0
0
0
20
Financial Forecasting
Based on analysts' estimates, GLUE EPS is projected to reach -0.364 in FY2026Q3, following reported EPS of -0.428 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.35
-0.38
-0.38
-0.36
-0.51
Actual
-0.54
-0.45
-0.43
--
--
Surprise
-53.39%
-17.25%
-12.20%
--
--
FAQs
What is Monte Rosa Therapeutics Inc's expected revenue for the next quarter?
Monte Rosa Therapeutics Inc's expected revenue is 24.20M.
What is Monte Rosa Therapeutics Inc's price target?
Analysts forecast that Monte Rosa Therapeutics Inc's price target is USD 28.80, with the highest forecast at USD 37.00 and the lowest forecast at USD 25.00.
How have Monte Rosa Therapeutics IncGLUE's recent earnings per share performed?
The market expectation was USD -0.43, while Monte Rosa Therapeutics IncGLUE's earnings per share (EPS) for the previous quarter was USD -0.45. EPS for the next quarter is expected at USD -0.36.
What is the analyst rating for Monte Rosa Therapeutics Inc?
Based on the ratings of Monte Rosa Therapeutics Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.